Milind Deshpande
Founder bei SPERO THERAPEUTICS, INC.
Vermögen: 28 301 $ am 31.03.2024
Profil
Milind S.
Deshpande is the founder of Spero Therapeutics, Inc. (founded in 2014) where he holds the title of Independent Director.
He is currently the President, Chief Executive Officer & Director at Nayan Therapeutics, Inc. (since 2019), the Chief Executive Officer & Board Member at Santi Therapeutics, Inc. (since 2019), the Chairman at Avilar Therapeutics, Inc. (since 2020), a Board Member at Clear Creek Bio, Inc. (since 2020), and a Venture Partner at RA Capital Management LP (Private Equity) (since 2018).
Previously, he served as the Chief Executive Officer & Director at Achillion Pharmaceuticals, Inc. (2001-2018), the Associate Director-Lead Discovery at Bristol-Myers Squibb Pharmaceutical Research Institute (1991-2001), and a Faculty Member at Boston University School of Medicine (1988-1991).
Dr. Deshpande obtained his doctorate degree from The Ohio University in 1986.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SPERO THERAPEUTICS, INC.
0,03% | 08.03.2024 | 16 454 ( 0,03% ) | 28 301 $ | 31.03.2024 |
Aktive Positionen von Milind Deshpande
| Unternehmen | Position | Beginn |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Founder | 01.01.2014 |
Nayan Therapeutics, Inc.
 Nayan Therapeutics, Inc. BiotechnologyHealth Technology Nayan Therapeutics, Inc. operates as a biotechnology company. It focuses on small molecule development for oscular disorders involving rod degeneration. The company is headquartered in Medfield, MA. | Chief Executive Officer | 01.02.2019 |
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Chief Executive Officer | 01.12.2019 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01.10.2018 |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Director/Board Member | 01.09.2020 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Chairman | 01.01.2020 |
Ehemalige bekannte Positionen von Milind Deshpande
| Unternehmen | Position | Ende |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | Chief Executive Officer | 02.05.2018 |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01.01.2001 |
| Boston University School of Medicine | Corporate Officer/Principal | 01.01.1991 |
Ausbildung von Milind Deshpande
| The Ohio University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SPERO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
| Bristol-Myers Squibb Pharmaceutical Research Institute | |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Nayan Therapeutics, Inc.
Nayan Therapeutics, Inc. BiotechnologyHealth Technology Nayan Therapeutics, Inc. operates as a biotechnology company. It focuses on small molecule development for oscular disorders involving rod degeneration. The company is headquartered in Medfield, MA. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Santi Therapeutics, Inc.
Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Health Technology |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
